生脉饮口服液治疗小儿扩张型心肌病临床疗效观察

发布时间：2018-03-01 13:36

本文关键词： 生脉饮口服液扩张型心肌病小儿心功能　出处：《中药药理与临床》2017年05期 　论文类型：期刊论文

【摘要】：目的:观察生脉饮口服液治疗小儿扩张型心肌病临床疗效。方法:我院儿科74例扩张型心肌病患儿(2013年1月至2015年12月)为对象,将其随机分为2组,均给予常规方案治疗,其中观察组另给予生脉饮口服液,分析该生脉饮口服液对该疾病是否有益。结果:(1)观察组治疗后的总有效率为91.89%,高于对照组70.27%。治疗后,观察组LVEF、LVSD、LVDD分别为(45.13±3.27%、40.95±2.26mm、42.95±2.14mm),均明显优于对照组(40.18±3.16%、45.08±2.35mm、47.23±2.30mm)。(3)治疗后,观察组SDNN、SDANN、r MSDD、p NN50分别为(127.9±7.8ms、119.4±7.2ms、29.31±2.52ms、17.35±1.04%),均明显高于对照组(115.8±7.1ms、104.5±6.9ms、25.82±2.44ms、13.28±0.98%)。(4)观察组不良反应率为5.41%,略低于对照组13.51%,但组间差异无统计学意义。(5)治疗开始起1年内,对照组死亡6例(16.22%),和观察组5例(13.51%)比,差异无统计学意义。结论:生脉饮口服液可改善扩张型心肌病患儿心功能,增加治疗效果,且用药安全。
[Abstract]:Objective: to observe the clinical efficacy of Shengmaiyin oral liquid in treating dilated cardiomyopathy in children. Methods: 74 pediatric children with dilated cardiomyopathy (January 2013 to December 2015) were randomly divided into two groups. The observation group was given Shengmaiyin oral liquid, and analyzed whether the Shengmaiyin oral liquid was beneficial to the disease. Results the total effective rate of the observation group after treatment was 91.89, which was higher than that of the control group 70.27.After the treatment, the total effective rate of the observation group was 91.89, higher than that of the control group 70.27. The LVDD of LVSD in the observation group was 45.13 卤3.27 and 40.95 卤2.26mm and 42.95 卤2.14mm respectively, which was significantly better than that in the control group (40.18 卤3.16mm / 45.08 卤2.35mm / 47.23 卤2.30mm / L). The adverse reaction rate of the observation group was 5.41, slightly lower than that of the control group 13.51, but there was no significant difference between the control group and the control group within one year after the beginning of the treatment, 6 cases of death in the control group were 16.22.1%, compared with 5 cases in the observation group, which were significantly higher than that in the control group (115.8 卤7.1 Ms), 25.82 卤2.44 ms13.28 卤0.98ms.4.The adverse reaction rate in the observation group was slightly lower than that in the control group 13.51, but there was no significant difference between the two groups within one year after the beginning of treatment, there were 6 cases of death in the control group and 13.51% in the control group. Conclusion: Shengmaiyin oral liquid can improve the heart function of children with dilated cardiomyopathy.
【作者单位】：河南大学淮河医院;
【分类号】：R272

【相似文献】